ClinicalTrials.gg
CompletedNCT01973920Updated Apr 18, 2018

Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study

A Phase 2 interventional study of Oshadi Icp in Diabetes Mellitus, Insulin-Dependent and Type 1, sponsored by Oshadi Drug Administration. Completed at 1 site in Israel. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2018-04-18.

Sponsored by Oshadi Drug Administration · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus — 1 open to participants now, 2 under way, none of them phase 3. Insulin · Diabetes Mellitus.

Enrollment
42nd of 49
12 · median 74
Started
2013
with 4 others
Phase 2
10 of 51
none open now
Registered
39th of 51
by date
Lead sponsor
2 of 51
Oshadi Drug Administration

Among the 51 studies testing insulin in Diabetes Mellitus, this one is the 42nd largest by enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2013, is one of 10 in phase 2, and was the 39th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 51 studies testing insulin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, or all of them as a file.
02

Study summary

Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone. The current methods of insulin therapy for diabetic patients are multiple daily injection therapy and continuous subcutaneous insulin infusion with an external pump. This rout of administration may lead to hyperinsulinemia as insulin is administered in a non physiological way, targeting mainly extra hepatic tissues (muscle, fat). A method of providing insulin without the need for injections has been a goal in drug delivery.

Oshadi Drug Administration Ltd. has developed oral carrier for proteins based on biochemistry and quantum theory of biochemical reactions. The carrier enables the absorption of proteins from the gastrointestinal tract in their full structure. Oshadi has also developed the Oshadi Icp - insulin, proinsulin and C-peptide in Oshadi carrier, administrated orally. This study was design in order to evaluate the safety and feasibility of multiple administrations of Oshadi Icp for home use. The study will be a multiple-dose, open-label non-randomized study in patients with Type 1 diabetes, with periodic dose adjustments. The study will include 4 weeks of multiple-dose administration of Oshadi oral insulin (Oshadi Icp) at home and in study center for the determination of the efficacy, safety and pharmacodynamic effects of Oshadi Icp.

03

Conditions studied

  • Diabetes Mellitus
  • Insulin-Dependent
  • Type 1

Browse trials for

Keywords

  • Diabetes Mellitus
  • Oral Insulin
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes mellitus (according to ADA criteria) for more than 3 year.
  • Male/female 21 years old and older.
  • ≥18.5 and ≤25
  • Female of childbearing age must commit to avoid pregnancy and use during the study.
  • Patients must understand and be willing to give written prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.

Exclusion criteria

Exclusion Criteria:

  • Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
  • Symptomatic DKA (diabetic ketoacidosis)in the last 6 months
  • Patients with positive or (hepatitis C virus)serology or positive at screening.
  • History or evidence of any active liver disease.
  • History of epilepsy.
  • One or more episodes of sever hypoglycemia during the last 12 months
  • History of hypoglycemic unawareness.
  • C-peptide >3 mg/ml (fasting)
  • Total average daily insulin dosage ≥1 IU/kg of body weight.
  • Polycystic ovary syndrome
  • Acanthosis nigricans
  • 6.5% > or HbA1c >10%
  • \<60 (epidermal growth factor receptor).
  • Female patients who are breastfeeding or have a positive pregnancy test at screening or at any time during the study and not willing to practice during study period.
  • Inability to give written
  • History of alcohol or drug abuse within 6 months of screening.
  • Patients who have a positive urine drug screen for substances of abuse (benzodiazepine, THC (tetrahydrocannabinol), opiates, amphetamines, cocaine) at the screening.
  • Mental disorders.
  • Significant swallowing disorders
  • Digestive disorders
  • Small bowel surgery
  • Any intercurrent disease during the last week prior to screening which in the judgment of the investigator might affect blood glucose level.
  • Any infectious disease developed during the 4 weeks prior to the study.
  • Malabsorption disorders.
  • Any significant abnormality by principal investigator in the baseline laboratory evaluation: liver and kidney functions, electrolytes, albumin, lipase, TSH (thyroid-stimulating hormone), , white blood cell count and differential, .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Oshadi Icp

    Oshadi Icp oral insulin,

    Drug: Oshadi Icp

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events and serious adverse events occurence

    Time frame: last follow-up visit (day 60)

Secondary outcomes

  1. To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve

    Time frame: Last administration day (day 37)

Other outcomes

  1. Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs routine use

    Time frame: Last administration day (day 37)

07

Study locations

1 site
  • Assaf-Harofeh Medical Center
    Zerifin, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Feb 2017, 38 months.

Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 38 months is above that.

Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2013
First posted
Nov 1, 2013
StartActual
Dec 2013
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Last update
Apr 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01973920
Lead sponsor
Oshadi Drug Administration
Responsible party
Sponsor
First posted
Nov 1, 2013
Start date
Dec 2013
Primary completion
Feb 2017
Completion
Feb 2017
Last update
Apr 18, 2018

Study contacts

Marianna Rachmiel, Dr.
principal investigator · Assaf-Harofeh Medical Center, Israel
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion